About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Prenetics Global (NASDAQ: PRE): Bending Biotech with Beckham

As the global population ages and the prevalence of chronic diseases rises, there is an increasing demand for innovative solutions that can enhance prevention, diagnosis, and treatment. The health sciences industry is undergoing a significant transformation, driven by advancements in genomics, personalized medicine, and early detection technologies. One major example is the global cancer diagnostics market, which was valued at USD 19.5 billion in 2023 and is expected to reach USD 54.6 billion by 2032, growing at a CAGR of 12.1% during the forecast period. In this dynamic landscape, one company has been making waves as of recent, Prenetics Global Limited (NASDAQ: PRE).

PRE: A Key Player in Health Innovation

Prenetics Global Limited (NASDAQ: PRE): a genomics-driven health sciences company, is making significant strides in the sector. The company operates through three primary units: CircleDNA, Insighta, and ACT Genomics, each contributing significantly to its mission of improving lives through science.

  • CircleDNA: Offers one of the most comprehensive consumer DNA tests available, utilizing whole exome sequencing. This test provides extensive insights into an individual's genetic predispositions, promoting proactive health measures and personalized wellness plans.

  • Insighta: A $200 million joint venture with renowned scientist Professor Dennis Lo, focuses on developing multi-cancer early detection technologies. The goal is to create a simple blood test that can detect multiple types of cancer at early stages, making early detection more accessible and affordable globally.

  • ACT Genomics: The first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors through its ACTOnco test. This milestone enables personalized cancer treatments based on detailed genetic profiles, significantly enhancing treatment efficacy.

Financial Performance and Strategic Milestones

Prenetics Global has demonstrated robust financial performance. On June 19, 2024, the company announced its unaudited financial results for the first quarter ending March 31, 2024. The company reported revenue from continuing operations of $6.4 million, a notable 30.2% increase compared to the first quarter of 2023. Gross profit from continuing operations surged to $3.8 million, reflecting a 159.8% increase from the previous year. Adjusted EBITDA from continuing operations improved by 55.9%, resulting in a loss of $4.1 million. Additionally, the company maintained a robust cash position with $86.6 million in cash and other short-term assets as of March 31, 2024. Insighta held a cash balance of $79.8 million on the same date.

Danny Yeung, Chief Executive Officer and Co-Founder of PRE, remarked, "The first quarter of 2024 marked a good start for our company, showcasing solid growth in revenue and gross profit. These results demonstrate firm governance of our financial position with no debt supported by a resilient and talented team."

Focus on the US Market

Prenetics Global is shifting towards the US consumer healthcare market to expand access to their health solutions. This move includes establishing dual headquarters to capitalize on new opportunities both domestically and globally. Yeung emphasized, "As we enter the second half of 2024, we are making significant strides in our strategic realignment with a keen focus on the consumer healthcare market in the USA. Our purpose remains dedicated to our science-first approach in our pivot to consumer healthcare to broaden accessibility to science-based health and wellness."

Recent Appointments and Board Changes

On July 1, 2024, PRE announced the addition of Kathryn M. Henry and David Vanderveen as independent directors to the company's Board of Directors. CEO Danny Yeung noted, "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness."

Partnership with David Beckham

On July 11, 2024, Prenetics Global announced a new partnership with former international footballer, entrepreneur, and philanthropist David Beckham. Beckham has become a strategic investor in the business, and together with PRE, they will co-found a new health and wellness brand, IM8. Beckham expressed his excitement about the partnership, saying, "Throughout my life and career, I've been fortunate to have access to the best medical professionals, nutrition experts, and fitness coaches. Their guidance has been crucial to my health and well-being. That’s why I am excited to be working with PRE - a company that is dedicated to innovative, world-leading scientific advancements in health - as a co-founding partner and ambassador for IM8.”

Danny Yeung highlighted the significance of this collaboration, stating, "This partnership with David marks a transformative era for PRE in global health innovation and wellness. David epitomizes the values of discipline, teamwork, and health, aligning perfectly with PRE's core principles. Working closely with David these past months, I've been consistently inspired by his vision for accessible health for all. His passion and commitment are truly extraordinary. With IM8, we have a unique opportunity to contribute meaningfully to the consumer health and wellness industry."

Conclusion

Prenetics Global Limited (NASDAQ: PREis making significant progress in the genomics and health sciences sectors, with a strong focus on cancer prevention, detection, and treatment. The company's recent financial performance, strategic focus on the US market, promising clinical trials, and high-profile partnership with David Beckham highlight its potential for continued growth and innovation. Investors interested in genomics and health sciences may want to keep a close eye on PRE.

Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.  

 

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.